tbuckley/cabot-search huggingface dataset:
Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC)
Authors: E. Vokes, M. Socinski, D.R. Spigel, L. Paz-Ares, R. Kurek, S. Nanda, G. Grau, J. Shahidi, N. Thatcher, D. Gandara
Journal: Annals of Oncology (2016)
P08.52 Proton therapy re-Irradiation in large-volume recurrent glioblastoma.
Authors: D. Amelio, L. Widesott, S. Vennarini, F. Fellin, F. Maines, R. Righetto, S. Lorentini, P. Farace, M. Schwarz, M. Amichetti
Journal: Neuro-Oncology (2016)

AbstractPurpose:To report preliminary results of re-irradiation with proton therapy (PT) in large-volume recurrent glioblastoma (rGBM).Matherial/Methods:Between January and December 2015 ten patients (pts) with rGBM were re-irradiated with PT. All pts were previously treated with photon radiotherapy (60 Gy) with concomitant and adjuvant TMZ for 1–20 cycles (median, 7). Seven pts were re-irradiated at first relapse/progression. Four patients were re-irradiated after partial tumor resection. Median age and Karnofsky performance status at re-irradiation were 57 years (range, 41–68) and 80%, (range, 70–100), respectively. Median time between prior radiotherapy and PT was 9 months (range, 5–24). Target definition was based on CT, MR, and 18F-DOPA PET imaging. GTV included any area of contrast enhancement after contrast medium administration plus any pathological PET uptake regions. CTV was generated by adding to GTV a 3-mm uniform margin manually corrected in proximity of anatomical barriers. CTV was expanded by 4 mm to create PTV. Median PTV volume was 90 cc (range, 46–231). All pts received 36 GyRBE in 18 fractions. Four pts also received concomitant temozolomide (75 mg/m2/die, 7 days/week). All pts were treated with active beam scanning PT using 2–3 fields with single field optimization technique.Results:All pts completed the treatment without breaks. Registered acute side effects (according to Common Terminology Criteria for Adverse Events version 4.0 - CTCAE) include grade 1–2 skin erythema, alopecia, fatigue, conjunctivitis, concentration impairment, dysphasia, and headache. There were no grade 3 or higher toxicities. One patient developed grade 1 neutropenia. Five pts started PT under steroids (2–7 mg/daily); two of them reduced the dose during PT, while three kept the same steroids dose. None of remaining pts needed steroids therapy. Registered late side effects (according to CTCAE version 4.0) include grade 1–2 alopecia, fatigue, concentration impairment, and dysphasia. During follow-up two pts (20%) developed radionecrosis (diagnosed at imaging) with mild symptoms controlled with steroids. There were no grade 3 or higher toxicities. The median progression-free survival (PFS) was 6.4 months, while the 3-, 6- and 9-month PFS rates were 80%, 67% and 22%, respectively. Median overall survival (OS) after PT was not achieved, while the 6- and 12-month survival after PT rates were 100% and 60%, respectively.Conclusion:PT re-irradiation of large-volume rGBM showed to be feasible and safe even with concomitant chemotherapy administration. Despite the small number of patients and the retrospective nature of the study PFS and OS rates were promising and deserve further evaluation in a larger pts sample.
Treatment Acute Myeloid Leukemia Using Cytoreductive Chemotherapy Cytarabine (Ara-C) Followed Azacitidine (AZA) Maintenance: A Real Life Single Center Experience
Authors: Rosa Greco, Annamaria Petrungaro, Anna Grazia Recchia, Laura De Stefano, Sabrina Bossio, Angela Palummo, Giovanni Iaquinta, Francesca Storino, Nadia Caruso, Massimo Gentile, Antonino Neri, Ernesto Vigna, Fortunato Morabito
Journal: Blood (2016)
Final analysis of patient-reported-outcomes (PRO) and early intervention to toxicities as tools for improving compliance of patients with metastatic colorectal cancer (mCRC) treated with aflibercept + FOLFIRI (A-FOLFIRI) under real-world-conditions in Germany
Authors: R. Lipp, M. Feuerbach, F. Freigang, P. Brecht
Journal: Annals of Oncology (2016)
NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.
Authors: Frits van Rhee, Susann M. Szmania, Mindy Pomtree, Frank Zhan, Amberly Moreno, Nancy Rosen, Michele Fox, Bart Barlogie, John Shaughnessy, Ramesh Batchu, Guido J. Tricot
Journal: Blood (2004)
NCOG-08. SHORT DuLIP: VALUABLE ADDITION TO STANDARD LANGUAGE ASSESSMENT IN GLIOMA PATIENTS BEFORE AND AFTER SURGERY
Authors: Djaina Satoer, Elke De Witte, Arnaud Vincent, Peter Marien, Evy Visch-Brink
Journal: Neuro-Oncology (2016)

Awake surgery is the gold standard for eloquent area low-grade gliomas (LGG) to preserve cognition and Quality of Life (QoL). LGG patients often report mild language disturbances which cannot always be captured with “classical” language tests (e.g. Boston Naming Test). Therefore a sensitive protocol was designed: Dutch Linguistic Intraoperative Protocol (DuLIP) with production and perception tests at the linguistic levels: phonology, semantics, syntax. DuLIP appeared to be mostly suitable for intraoperative testing with many relatively “easy” items (possible influence of slight sedation). A shortened more complex version was needed for pre- and postoperative testing to detect mild disturbances. We present preliminary results of glioma patients assessed with short DuLIP and “classical” language tests. 21 patients (mean age 41.8) were included and tested pre- (N=21) and postoperatively (N=8) with: Short DuLIP: Production: 1) repetition (3-syllabic-words, compounds, non-words, sentences), 2) semantic-odd-picture-out (nouns, verbs), 3) sentence completion, Perception: 4) sentence judgment (phonology, semantics, syntax) measured with Accuracy (AC) and Reaction Time (RT). “Classical” tests: Boston Naming Test, Token Test, category and letter fluency. Preoperatively, patients’ performance was intact on all “classical” tests. Impairments were observed in short DuLIP: semantic-odd-picture-out (verbs), sentence completion, AC and RT of the semantic sentence judgment task and on RT of the phonological sentence judgment task (z≥-1.5). Postoperatively, 1 “classical” test deteriorated: letter fluency whereas Short DuLIP worsened on all 5 repetition subtests, sentence completion and RTs sentence judgement on all 3 subtests (z≥-1.5). AC of the semantic sentence judgment task improved (z<-1.5). Short DuLIP appeared to be more sensitive pre- and postoperatively to detect language disorders than most “classical” tests, with the emphasis on repetition and RT which could be relevant predictors for language outcome and QoL. Our preliminary results suggest that short DuLIP could be a valuable addition to standard language assessment used in glioma patients.
Prospective Evaluation of the NIH Staging Criteria in Chronic GVHD and Correlation to Quality of Life - Results of a German Multicenter Validation Trial.
Authors: Daniel Wolff, Philipp Y. Herzberg, Pia Heussner, Friederike Mumm, Stephanie von Harsdorf, Katrin Rieger, Hildegard Greinix, Joachim Hahn, Ernst Holler, Mathias Freund
Journal: Blood (2007)
Patient Characteristics, Quality-of-Life and Compliance with Deferoxamine in Patients with Transfusional Iron Overload: Results of ‘ISOSFER’ Study.
Authors: I. Thuret, C. Brun-Strang, D. Bachir, M. Hacini, B. Pegourie-Bandelier, M. Gardembas-Pain
Journal: Blood (2006)
Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)
Authors: William Blum, Rebecca Klisovic, Shujun Liu, Ramiro Garzon, Cheryl Kefauver, Zhongfa Liu, Jon Mickle, Hollie Devine, Steve Devine, Michael R Grever, Kenneth K Chan, Miguel Villalona-Calero, John C. Byrd, Guido Marcucci
Journal: Blood (2008)
The effect of tumor response on quality of life (QoL) in patients with <i>KRAS</i> wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study.
Authors: I. Griebsch, I. Lang, U. Sartorius, E. Van Cutsem
Journal: Journal of Clinical Oncology (2011)

476 Background: In the CRYSTAL study cetuximab (cet) added to first-line chemotherapy (CT) significantly improved tumor response compared with CT alone in patients (pts) with KRAS wild-type (wt) mCRC, confirming existing data in this setting. Response to CT has been reported to lead to a corresponding increase in QoL, and QoL scores to predict overall survival in mCRC. In this exploratory analysis tumor response and QoL was investigated in pts from the CRYSTAL study. Methods: Pts were classified as responders (Rs) or nonresponders (NRs) according to best overall response. QoL was assessed using single-item symptoms questions from the EORTC QLQ-C30 (q8-10, q12-18). Pts at baseline were considered symptomatic if they answered “quite a bit” or “very much” and asymptomatic if they answered “not at all” or “a little” to either one of the symptoms questions. Analysis was performed in all treatment groups (gps) on the change in symptoms in pts considered symptomatic or asymptomatic at baseline. Results: 471 of 627 KRAS wt pts assessed for QoL had baseline data showing they were symptomatic or asymptomatic. In pts asymptomatic at baseline (n=278) there were more Rs (58%) than NRs (42%). In pts symptomatic at baseline (n=193), there were less Rs (40%) than NRs (60%). At week 8 in all treatment gps, in pts symptomatic at baseline more Rs than NRs became asymptomatic (Table). In pts asymptomatic at baseline, in the CT + cet gp at week 8, 61% of Rs remained asymptomatic compared with 50% of NRs. Data from week 16 and 24 also showed trends in favor of Rs in symptomatic or asymptomatic pts at baseline and will be presented. Conclusions: Rs who are symptomatic at baseline experience higher symptom relief than NRs. Furthermore Rs who are asymptomatic at baseline are more likely to remain asymptomatic post baseline than NRs. These findings are independent of treatment. [Table: see text] [Table: see text]
P17.04 Radiomics analysis of primary central nervous system lymphoma (PCNSL) - A LOC network study
Authors: L. Royer-Perron, A. Bruno, M. Daniau, K. Labrèche, K. Mokhtari, L. Nguyen Them, C. Houillier, C. Soussain, K. Hoang-Xuan, A. Alentorn
Journal: Neuro-Oncology (2016)
A Novel Pharmacodynamic Perfusion Chamber Assay Reveals Superior and Unique Antithrombotic Activities of a Direct-Acting P2Y12 Antagonist, PRT128, Relative to Clopidogrel.
Authors: Pamela Conley, Marzena Jurek, Gillian Stephens, Ming He, Alok Finn, Herman Gold, Kevin Romanko, Daniel Gretler, David Phillips, Patrick Andre
Journal: Blood (2006)
GROWTH CHARACTERISTICS OF INFLUENZA VIRUS
Authors: W. Wilbur Ackermann, Hunein F. Maassab
Journal: The Journal of Experimental Medicine (1955)

A further analysis of the growth curve obtained in vitro for influenza virus in chorioallantoic membrane has been made using the viral inhibitor p-fluorophenylalanine. It has been found that p-fluorophenylalanine is phase-specific, does not interfere with the initiation of infection but rather acts during the productive period of the infectious sequence. The site of action of this fluoroderivative has been described relative to the site of action of methoxinine. By the use of this inhibitor in combination with methoxinine, it has been possible to recognize two stages of development which were not discernible from the usual growth curve. In a multicellular culture these two reactions, A and B, occur for the most part simultaneously, during the latent and productive periods. Reaction A is inhibited by methoxinine, but not by fluorophenylalanine. It begins early in the latent period and can proceed independent of reaction B. Reaction B is inhibited by fluorophenylalanine, but not by methoxinine, and it cannot proceed unless reaction A is proceeding or has operated for some prior interval.
Dacomitinib as first-line treatment of locally-advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): Interim analysis of an open-label, single-group, phase 2 trial
Authors: A. Necchi, D. Giardiello, D. Raggi, P. Giannatempo, N. Nicolai, M. Catanzaro, T. Torelli, D. Biasoni, L. Piva, S. Stagni, G. Calareso, E. Togliardi, L. Mariani, R. Salvioni
Journal: Annals of Oncology (2016)
Novel Mechanism of β0 Thalassemia: Missense Mutation of the Last Nucleotide of β Globin Exon 1 (G-&gt;C) Leads to Undetectable Transcript and Mutant Peptide.
Authors: Neeraj Agarwal, Mariluz P. Mojica-Henshaw, Ferdane Kutlar, Amos Gaikwad, Ching N. Ou, Abdullah Kutlar, Josef T. Prchal
Journal: Blood (2006)
Impact of c-kit mutations, including codons 557 and/or 558, on the recurrence-free survival after curative surgery in patients with GIST.
Authors: T. Watanabe, H. Cho, T. Yoshikawa, A. Tsuburaya, O. Kobayashi
Journal: Journal of Clinical Oncology (2011)

12 Background: Recently, c-kit exon 11 deletions, including codons 557 and/or 558, have been reported to predict a worse prognosis in GIST patients. However, it is difficult to prove the correlation between genotype and tumor aggressiveness in the imatinib- adjuvant era because exon 11 mutations respond well to imatinib. In this study, we evaluated the impact of c-kit mutational status on recurrence-free survival (RFS) after resection of primary GIST. Methods: Clinical and pathological characteristics of 89 GIST patients in our single institution study were retrospectively analyzed. Tumors were categorized into 4 subgroups based on their mutational locations; A1: mutated codons including neither 557 nor 558, A2: either 557 or 558, B1: only 557 and 558, B2: both 557 and 558. All of the patients underwent curative surgery, and none received adjuvant imatinib. The median duration of follow-up was 49 months. Results: Tumors originated from the stomach (n=75/89, 84%), small intestine (n=10), and colorectum (n=4). Mutation subgroup B was associated with both Fletcher and Miettinen high-risk categories. The 2-year recurrence free survival rate for A1, A2, B1, B2, was 84.9%, 85.7%, 50%, 57%, respectively. Group B2 had a significantly worse RFS than groups A1 (p=0.0004) and A2 (p=0.0014). Multivariate analysis for RFS indicated that only the mutational subgroup was a significant prognostic factor (p=0.03, HR=2.42). Conclusions: C-kit mutations, including both 557 and 558, affected the RFS of GIST patients after curative surgery, but those including either 557 or 558 did not. Our results indicate that the locations of c-kit mutations are associated with PFS, and they may therefore affect the selection of candidates with GIST for adjuvant imatinib. No significant financial relationships to disclose.
Phenotypic Variability in Genetic Hemochromatosis: Study of Five SNPs in a Cohort of 342 Compound Heterozygotes for the HFE Cys282Tyr / His63Asp Mutations
Authors: Gaelle Tachon, Marie-Paule Roth, Fabienne Calcoen, Celine Besson-Fournier, Michael Bismuth, Patricia Aguilar-Martinez
Journal: Blood (2015)
TIMP-3 Inhibition of Angiopoietin-1 Signaling Recruits Hematopoietic Stem Cells from the Bone Marrow Niche.
Authors: Hideaki Nakajima, Miyuki Ito, David Smookler, Fumi Shibata, Yumi Fukuchi, Yuko Goto-Koshino, Fumio Arai, Toshio Suda, Rama Khokha, Toshio Kitamura
Journal: Blood (2007)
Acetaminophen in Pregnancy and Adverse Childhood Neurodevelopment—Reply
Authors: Evie Stergiakouli, Anita Thapar, George Davey Smith
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP and IEWP) of the EBMT
Authors: Rafal Machowicz, Felipe Suarez, Wieslaw W Jedrzejczak, Dirk-Jan Eikema, Liesbeth C de Wreede, Henric-Jan Blok, Cecilia Isaksson, Hermann Einsele, Xavier Poiré, Manos Nikolousis, Jan-Erik Johansson, Guido Kobbe, Marco Zecca, Renate Arnold, Jose L. Diez-Martin, Stefan Schönland, Arjan C Lankester, Andrew Gennery, Nicolaus Kroeger
Journal: Blood (2016)
Birth Weight and the Risk of Testicular Cancer: Reply
Authors: Robert H. Depue, Malcolm C. Pike, Brian E. Henderson
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Birth Weight and the Risk of Testicular Cancer: Reply Get access Robert H. Depue, Robert H. Depue Search for other works by this author on: Oxford Academic PubMed Google Scholar Malcolm C. Pike, Malcolm C. Pike Search for other works by this author on: Oxford Academic PubMed Google Scholar Brian E. Henderson Brian E. Henderson Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 77, Issue 3, September 1986, Pages 829–830, https://doi.org/10.1093/jnci/77.3.829-a Published: 01 September 1986
An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort
Authors: S. Bozzarelli, L. Rimassa, L. Giordano, S. Sala, M.C. Tronconi, M. Baretti, N. Personeni, T. Pressiani, A. Santoro
Journal: Annals of Oncology (2016)
Gene Transfer of IL-7R alpha (IL-7Rα) on Antigen-Specific Cytotoxic T Cells (CTLs) Restores Their Ability To Respond to IL-7 Cytokine.
Authors: J.F. Vera, V. Hoyos, B. Savoldo, C. Quintarelli, G. Giordano-Attianese, A.E. Foster, Helen E. Heslop, C.M. Rooney, M.K. Brenner, G. Dotti
Journal: Blood (2007)
Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): Results from EXIST-1 and EXIST-2.
Authors: David Neal Franz, Christopher Kingswood, Sergiusz Jozwiak, Klemens Budde, Elena Belousova, Steven Sparagana, B. A. Zonnenberg, Michael Frost, Gaurav D. Shah, Jeremie Lebrec, James Ford, Creton Kalfoglou, David Chen, John Bissler
Journal: Journal of Clinical Oncology (2012)

10619 Background: The efficacy and safety of everolimus, an oral mTOR inhibitor, was assessed in two randomized, double-blind, placebo-controlled, phase 3 trials: EXIST-1 (NCT00789828) and EXIST-2 (NCT00790400). EXIST-1 examined everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) associated with TSC and EXIST-2 for the treatment of renal angiomyolipoma (AML) associated with either TSC or sporadic lymphangioleiomyomatosis. In each instance, everolimus was superior to placebo for the primary endpoints, SEGA and renal AML response rates. Inhibitors of mTOR have antiangiogenic effects on tumor growth in vitro and in vivo. Methods: Patients were randomized to receive everolimus (n=78) starting at 4.5 mg/m 2 /day (target trough, 5-15 ng/mL) or placebo (n=39) in EXIST-1 and 10 mg/day everolimus (n=79) or placebo (n=39) in EXIST-2. Plasma samples were taken at baseline and pre-dosing on day 1 of weeks 4, 12, 24, 36, and 48 of treatment. Angiogenic markers of interest were vascular endothelial growth factor (VEGF)-A and -D, placental growth factor (PlGF), soluble VEGF receptor-1 (sVEGFR1), soluble VEGF receptor 2 (sVEGFR2), c-Kit, and collagen type IV. Results: Compared with placebo, a sustained ~30% and ~60% increase in VEGF-A was observed in the everolimus arm of EXIST-1 and EXIST-2, respectively. A concomitant decrease in collagen type IV (~25% EXIST-1; ~45% EXIST-2) and sVEGFR2 (~25% both trials) was also observed in the everolimus arm. A sustained decrease (~60%) in VEGF-D was observed in the everolimus arm of EXIST-2, but not EXIST-1. In both studies, no change was observed in PlGF, sVEGFR1, or c-Kit plasma concentrations in the everolimus arm or any biomarkers evaluated in the placebo arm. Baseline sVEGFR2 and VEGF-D were ~40% and ~4-fold higher, respectively, while VEGF-A was ~50% lower in EXIST-2 compared with EXIST-1. A similar baseline plasma concentration for the other biomarkers was noted in both studies. Conclusions: Patients presenting with SEGA or renal AML associated with TSC had a reduction in plasma concentrations of sVEGFR2, collagen type IV, and VEGF-D (AML only) and an increase in VEGF-A. Everolimus may have antiangiogenic properties in TSC patients.
Real-world comparative effectiveness analysis of second-line (2L) nab-paclitaxel (nab-P) vs paclitaxel (Pac) in patients (Pts) with metastatic breast cancer (MBC)
Authors: C. Pelletier, M. Parisi, S. Glück, Q. Ni, F. Braiteh
Journal: Annals of Oncology (2016)
Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia Transformed from Ph-Negative Myeloproliferative Neoplasm: A Study from the Adult AML Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
Authors: Shinsuke Takagi, Kazuhiro Masuoka, Naoyuki Uchida, Mineo Kurokawa, Hirohisa Nakamae, Mitsuru Tsudo, Koji Iwato, Tatsuo Ichinohe, Yoshiko Atsuta, Akiyoshi Takami
Journal: Blood (2014)
A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma
Authors: Ajay K. Gopal, Ted Gooley, Joseph Rajendran, John M. Pagel, Darrell R. Fisher, David G. Maloney, Frederick R. Appelbaum, Andrew Shields, Oliver W. Press
Journal: Blood (2011)
Keep the door open for child refugees
Authors: Tom Moberly
Journal: BMJ (2017)

George W Hales/Fox Photos/Getty Images

Simon Wessely, president of the Royal College of Psychiatrists, drew on his family involvement in the story of the Kindertransport children when he argued last week that the United Kingdom shouldn’t close the door to unaccompanied child refugees. Between 1938 and 1940 over 9000 children, most of them Jewish, were brought from Germany, Austria, Czechoslovakia, and Poland to the UK as part of the Kindertransport rescue efforts. Pictured are children arriving from Vienna at London’s Liverpool Street station …
A Phase 1 Study of Dose-Dense 5-Aza-2′-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).
Authors: Guillermo Garcia-Manero, Deborah Thomas, Michael Rytting, Patrick A. Zweidler-McKay, Hui Yang, Zhihong Fang, Shaoqing Kuang, Samuel Dara, Susan O'Brien, Hagop M. Kantarjian
Journal: Blood (2009)
Pharmacokinetics (PK) and safety of carfilzomib (CFZ) in patients (Pts) with advanced malignancies and varying degrees of hepatic impairment (HI): an open-label, single-arm, phase 1 study
Authors: J. Brown, R. Plummer, T.M. Bauer, S. Anthony, J. Sarantopoulos, F. De Vos, M. White, M. Schupp, Y. Ou, U. Vaishampayan
Journal: Annals of Oncology (2016)
Long-Term HSC Donor Follow-up: Malignancy Incidences after Donation Are Identical Compared to a Matched Control Sample of Registered Donors, but Different to Expected General Population Rates
Authors: Thilo Mengling, Camila J. Hernandez Frederick, Daniel Fandel, Jürgen Sauter, Johannes Schetelig, Alexander H. Schmidt, Gerhard Ehninger
Journal: Blood (2015)
Cathepsin G, a Potent Platelet Aggregation Activator, Is Upregulated in Multiple Myeloma Patients during Treatment with Lenalidomide (Revlimid).
Authors: Rekha Pal, Ryan Kennedy, L. Renee Mansour, David Stirling, Markus Y. Mapara, G. David Roodman, Suzanne Lentzsch
Journal: Blood (2007)